C

Captor Capital Corp
CNSX:CPTR

Watchlist Manager
Captor Capital Corp
CNSX:CPTR
Watchlist
Price: 0.5 CAD 16.28%
Market Cap: 1.7m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CPTR stock under the Base Case scenario is hidden CAD. Compared to the current market price of 0.5 CAD, Captor Capital Corp is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPTR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

0.2
P/S
P/S
Price to Sales
0.2
vs History
77
vs Industry
93
Median 3Y
0.3
Median 5Y
7.5
Industry
2.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-15.6
Industry
21.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
50
Median 3Y
-5.3
Median 5Y
-40.3
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
36
Median 3Y
-3
Median 5Y
-25.7
Industry
24
More Details
0
P/B
P/B
Price to Book Value
0
vs History
96
vs Industry
82
Median 3Y
0.4
Median 5Y
6.6
Industry
2.2
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
92
Median 3Y
-0.2
Median 5Y
6.8
Industry
2.7
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
87
Median 3Y
-0.4
Median 5Y
18.1
Industry
5.3
More Details
13.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.1
vs History
0
vs Industry
48
Median 3Y
-5.7
Median 5Y
-30.1
Industry
12.9
More Details
6.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.2
vs History
14
vs Industry
35
Median 3Y
1.2
Median 5Y
-23.6
Industry
16.3
More Details
1.6
EV/OCF
EV/OCF
Enterprise Value to OCF
1.6
vs History
14
vs Industry
48
Median 3Y
-3.1
Median 5Y
-36.2
Industry
15.2
More Details
1.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
1.6
vs History
14
vs Industry
37
Median 3Y
-3.3
Median 5Y
-34
Industry
17.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
83
Median 3Y
-0.3
Median 5Y
6.8
Industry
1.9
More Details

Multiples Across Competitors

CPTR Competitors Multiples
Captor Capital Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Captor Capital Corp
CNSX:CPTR
1.7m CAD 0.2 -0.2 13.1 6.2
US
Eli Lilly and Co
NYSE:LLY
738.3B USD 15.1 66.5 35.7 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.2B USD 4.2 17.2 12.5 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.3 18.4 12.7 14.6
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.4 24.5 9.2 10.8
CH
Novartis AG
SIX:NOVN
187.7B CHF 4.4 18.3 10.8 14.4
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP 4 28.1 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
205.5B USD 3.2 11.8 8.8 10.6
IE
Endo International PLC
LSE:0Y5F
184.8B USD 79.7 -63.2 294 737.3
US
Pfizer Inc
NYSE:PFE
140.7B USD 2.3 17.9 7.6 10.7
P/E Multiple
Earnings Growth PEG
CA
C
Captor Capital Corp
CNSX:CPTR
Average P/E: 25.3
Negative Multiple: -0.2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.5
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.4
18%
1
CH
Roche Holding AG
SIX:ROG
24.5
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
Captor Capital Corp
CNSX:CPTR
Average EV/EBITDA: 398.3
13.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
13%
1
CH
Roche Holding AG
SIX:ROG
9.2
5%
1.8
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
Captor Capital Corp
CNSX:CPTR
Average EV/EBIT: 1 705.4
6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1

See Also

Summary
CPTR intrinsic value, competitors valuation, and company profile.
DCF Valuation
CPTR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CPTR stock valuation using valuation multiples.
Wall Street Estimates
CPTR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CPTR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.